Vivera is an innovative, science-driven pharmaceutical company focused on novel therapies for a variety of indications. In addition to its pharmaceutical, medical device, advanced diagnostics, medical supplies, medical technologies, and neurosciences, the Company has global exclusivity to license the patented and patent-pending TABMELT®️ sublingual drug-delivery system for the pharmaceutical use of therapeutic compounds. Vivera is vertically integrated with technology, manufacturing capabilities, and distribution for its products.
Vivera is committed to the continued research and development of innovative therapies across the spectrum. We believe that now is the time to combat some of the most unprecedented issues affecting patients and their caregivers by redefining the landscape with safe, yet effective, non-addictive treatment alternatives for pain management and the latest in medical device technologies. From strength in vision to channeled realization, we believe the path forward begins with the requirement to put patients first. Our foremost mission is to enhance the lives of millions of neighbors, families, and the leaders of tomorrow, through ceaseless development of life-changing new therapies.
Vivera is dedicated to making a positive difference for vulnerable communities across the world. Through our non-profit organization, Vivera Cares, we are helping underserved communities, like Tribal Nations and frontline workers, access the resources they need to keep their communities safe and healthy. With our continued support, we can envision a brighter future for our communities, patients, and providers.
NEWPORT BEACH, Calif. – Vivera Pharmaceuticals today announced the introduction of Vivera BioSciences, a new division of the Company focused exclusively on research and innovation
NEWPORT BEACH, Calif.- Vivera Pharmaceuticals is proud to announce the Company’s Vice President of Sales, Olivia Karpinski, has been selected as a nominee by Los Angeles
NEWPORT BEACH, Calif. – Vivera Pharmaceuticals, Inc., in partnership with DoctorsOne Healthcare Systems (Doc1 Health) and the Manny Pacquiao Foundation, announced the launch of a joint
NEWPORT BEACH, Calif. – Vivera Pharmaceuticals, Inc. continues to move forward in its defamation lawsuit filed in Virginia state court against USA Today and its
NEWPORT BEACH, Calif. – The U.S. Patent and Trademark Office (USPTO) has granted Vivera’s ZICOH® technology a second U.S. Patent, No. 11,090,449. Vivera is pleased to
NEWPORT BEACH, Calif. – Vivera Pharmaceuticals, Inc. (Vivera) today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,083,850 for ZICOH®,
About one in five U.S. adults live with a mental illness. One in 25 live with a serious mental illness. Despite its prevalence, there is
Did you know that pain is the number one reason Americans access the health care system? Chronic pain, which is pain that persists on most
Mental health has been a topic of interest in the sports world for a while, as an increasing number of athletes are stepping forward to
When people think about drug abuse, they often think about illicit drugs like heroin or cocaine. While these drugs are widely abused, many people also
According to the Centers for Disease Control and Prevention (CDC), one in five U.S. adults experiences mental illness every year, meaning there’s a good chance you
When a person takes opioids for a prolonged period of time, they often develop a tolerance to the drug, meaning they need a larger dose
Innovation is the lifeblood of Vivera. With six divisions, each focused on a specific crisis response, Vivera’s vertically integrated structure has created an agile and responsive model.
Vivera is working to change the future of drug delivery, medical device, and medical technologies at home and across the globe with its extensive intellectual property portfolio.
Copyright © 2021 Vivera Pharmaceuticals, Inc. All rights reserved.
This information – including product information – is intended only for certified clinicians in the United States. The products discussed herein may have different labeling in different countries. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
English
Arabic
Armenian
Chinese (Simplified)
Chinese (Traditional)
Czech
Dutch
Tagalog
French
Frisian
German
Irish
Italian
Korean
Farsi
Polish
Portuguese
Romanian
Russian
Spanish
Swedish
Ukrainian
Vietnamese